Lead Sponsor

Merck Sharp & Dohme LLC

Age

18 - 60 years

Sex

MALE

Healthy Volunteers

No

•Body Mass Index (BMI) of 18 to ≤ 37 kg/m\^2
•Clinical diagnosis of chronic HCV infection defined by positive serology for HCV for at least 6 months and detectable HCV RNA in peripheral blood ≥105 IU/mL at screening
•Participant must be infected with HCV GT1a, GT1b, or GT 3

•Co-infection with GT1 and GT3
•Estimated creatinine clearance of ≤70 mL/min based on the Cockcroft-Gault equation
•History of stroke, chronic seizures, or major neurological disorder
•History of clinically significant endocrine, gastrointestinal (excepting HCV infection), cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases
•History of neoplastic disease
•Positive Hepatitis B surface antigen at the pre-study (screening) visit
•Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to the prestudy (screening) visit.
•Previous treatments (s) with nonstructural protein 5A (NS5A) inhibitors
•\<4 weeks since administration of any experimental protease inhibitor
•Previous exposure to interferon-alpha and/or ribavirin within 3 month prior to the first dose of elbasvir in the study
•Clinical or laboratory evidence of advanced or decompensated liver disease